Dialkoxynaphtho[2,3-c]furanone Derivatives for Selective Anti-inflammatory and Antiviral Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for allergic diseases and COVID-19 are limited in effectiveness and have significant side effects, and there is a need for new compounds that can effectively treat respiratory and viral infections, including SARS-COV-2, influenza, dengue, and Zika viruses.
Innovation Solution
Development of 6,7-dialkoxynaphtho[2,3-c]furan-1(3H)-one derivatives and their pharmaceutical compositions for use in treating or preventing allergic diseases, respiratory diseases, and viral infections, including SARS-COV-2, by administering the compounds to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids are used to suppress immune responses for allergic diseases, then anti-inflammatory effect is improved, but side effects worsen due to non-selective immune suppression
Solution Approach 1:
The patent applies local quality by designing a compound with specific functional groups (dialkoxy substitution pattern, furanone core) that enable selective binding to specific immune targets (e.g., T-cell receptors, cytokine pathways) rather than broad-spectrum immune suppression. This selectivity allows anti-inflammatory action at specific pathological sites while preserving overall immune function, thereby reducing systemic side effects.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure parameters of the compound (varying alkoxy group positions and types at 6,7-positions, substituent variations at 4-position) to optimize the balance between anti-inflammatory potency and selectivity. These structural parameter adjustments fine-tune the compound's affinity for target receptors versus off-target interactions, resolving the contradiction between efficacy and side effects.
2Ease of operation
If anti-leukotrienes are used for allergic diseases, then symptom alleviation is improved, but effectiveness on asthma treatment worsens compared to inhaler corticosteroids
Solution Approach 1:
The patent applies universality by designing a multi-functional compound that can simultaneously target multiple pathways involved in allergic inflammation and asthma pathogenesis (e.g., leukotriene synthesis, cytokine release, eosinophil activation). This multi-target approach provides both symptom relief and disease control, making the compound effective for both mild allergic symptoms and severe asthma, thus resolving the limitation of single-mechanism anti-leukotrienes.
3Reliability
If anti-IgE antibody or anti-IL-5 antibody therapeutic agents are used for severe asthma, then treatment effectiveness is improved, but cost worsens
Solution Approach 1:
The patent applies this principle by developing a small molecule compound that can be synthesized through conventional chemical processes rather than complex biotechnology manufacturing required for monoclonal antibodies. The compound structure (naphtho[2,3-c]furan-1(3H)-one core with dialkoxy substituents) allows for scalable synthesis using standard pharmaceutical manufacturing techniques, significantly reducing production costs while maintaining therapeutic effectiveness for severe asthma.
4Reliability
If Remdesivir is used for SARS-COV-2 treatment, then viral infection treatment is attempted, but effect is questioned and availability is limited
Solution Approach 1:
The patent applies segmentation by designing a compound with modular structure where the core naphtho[2,3-c]furan-1(3H)-one framework can be independently synthesized and then combined with various alkoxy substituent groups. This modular approach allows for parallel synthesis of multiple derivatives and simplifies scale-up production, improving availability compared to complex antiviral agents like Remdesivir that require multi-step nucleoside analog synthesis.
Data Source
AI summary
The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprising same. The pharmaceutical composition has excellent antiviral efficacy, thereby having a preventive or treatment effect on viral infectious disease such as SARS-COV-2, and exhibits an inhibitory effect on IL-5 expression and thus has a preventive or treatment effect on respiratory disease or allergic disease.